Intensity Therapeutics Restarts Key Cancer Trials, Cash at $9.5M
INTS sits 19% above its 52-week low of $3.51 on light trading volume (0.4× avg).
Summary
Intensity Therapeutics reported Q2 2026 results with $9.5 million in cash as of June 30, 2026, down from $10.2 million at Q1 end, and a net loss that widened due to rising R&D costs. The company has resumed enrollment in its Phase 3 INVINCIBLE-3 soft tissue sarcoma study at limited U.S. sites and restarted patient treatment in the Phase 2 INVINCIBLE-4 triple-negative breast cancer trial. Preliminary data from INVINCIBLE-4 showed a 71% pathological complete response in the INT230-6 arm versus 42% for standard of care. The company raised $1.6 million under its $60 million ATM facility in Q2 and an additional $1.3 million after quarter end. With a market cap near $11.6 million and a going concern warning, the cash runway remains tight, but trial restarts signal progress. A conference call at 8:00 a.m. ET today may provide further details on funding and enrollment timelines.
At the time of this announcement, INTS was trading at $4.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6M. The 52-week trading range was $3.51 to $43.50. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.